OTCBB:IVBXF

Innovent Biologics Stock News

Healthcare > Biotechnology

Buy IVBXF

*Your capital is at risk

$10.24

-0.190 (-1.83%)

At Close: Jun 03, 2026

2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs

08:00pm, Sunday, 27'th Apr 2025

SAN FRANCISCO and SUZHOU, China , April 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial

Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer

08:00pm, Friday, 25'th Apr 2025

SAN FRANCISCO and SUZHOU,China, April 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ

Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting

07:00pm, Wednesday, 23'rd Apr 2025

SAN FRANCISCO and SUZHOU,China, April 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ

Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

09:19pm, Sunday, 30'th Mar 2025

SAN FRANCISCO and SUZHOU, China , March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting

09:12pm, Wednesday, 26'th Mar 2025

SAN FRANCISCO and SUZHOU, China , March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial

Innovent Announces 2024 Annual Results and Business Updates

06:21am, Wednesday, 26'th Mar 2025

First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China , March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a w

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

08:00pm, Sunday, 23'rd Mar 2025

SAN FRANCISCO and SUZHOU, China , March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercia

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China

08:55pm, Tuesday, 18'th Mar 2025

SAN FRANCISCO and SUZHOU, China , March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercia

China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease

04:35am, Friday, 14'th Mar 2025

SAN FRANCISCO and SUZHOU, China , March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerci

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

07:00pm, Sunday, 02'nd Mar 2025

SAN FRANCISCO and SUZHOU, China , March 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercia

NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer

06:50pm, Sunday, 23'rd Feb 2025

SAN FRANCISCO and SUZHOU, China , Feb. 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

07:00pm, Sunday, 16'th Feb 2025

SAN FRANCISCO and SUZHOU, China , Feb. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial

Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

07:00pm, Thursday, 16'th Jan 2025

SAN FRANCISCO and SUZHOU, China , Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

06:00pm, Thursday, 16'th Jan 2025

Advancing into new stage of sustainable growth and global innovation SAN FRANCISCO and SUZHOU, China , Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

07:00pm, Wednesday, 15'th Jan 2025

SAN FRANCISCO and SUZHOU, China , Jan. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by